)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Scholar Rock Holding (SRRK) investor relations material
Scholar Rock Holding Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
FDA accepted apitegromab BLA under priority review with a PDUFA date of September 22, 2025; U.S. commercial launch preparations underway and EU launch anticipated in 2026.
Positive Phase 3 SAPPHIRE and Phase 2 EMBRAZE trial results for apitegromab in SMA and obesity, showing significant motor function improvement and lean mass preservation.
Expanding apitegromab into additional neuromuscular diseases (DMD, FSHD) and advancing pipeline assets, including SRK-439.
Management transition with new CEO and executive team effective April 27, 2025.
Disciplined capital allocation and commercial buildout to support launch and pipeline expansion.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $295 million as of June 30, 2025, expected to fund operations into 2027.
Net loss for Q2 2025 was $110 million ($0.98 per share), with no product revenue recorded.
R&D expenses rose to $62.4 million in Q2 2025, driven by drug supply, employee, and transition costs.
G&A expenses increased to $49.7 million in Q2 2025, mainly due to stock-based compensation and launch readiness.
$50 million drawn under Oxford loan facility; up to $150 million additional available upon milestones.
Outlook and guidance
U.S. commercial launch of apitegromab planned for 2025, pending FDA approval; European launch targeted for 2026.
Phase 2 OPAL trial in SMA infants and toddlers to begin in Q3 2025.
IND filing for SRK-439 expected in the second half of 2025.
Cash runway projected to support commercial and development programs into 2027.
Additional capital may be required for full program execution.
Assess apitegromab's competitive advantage.
Elaborate on SRK-439's myostatin selectivity.
Explain the increase in G&A expenses.
What are the specific CDMO observations?
Assess payer receptiveness to apitegromab.
Detail plans for apitegromab in DMD/FSHD.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Scholar Rock Holding earnings date
Q3 202511 Nov, 2025
Next Scholar Rock Holding earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Scholar Rock Holding Corp is a biopharmaceutical company engaged in the discovery and development of innovative medicines for the treatment of serious diseases, with a focus on those in which signaling by protein growth factors plays a fundamental role. The company's research and development efforts include Apitegromab, an inhibitor of the activation of latent myostatin that has completed Phase 3 clinical trials for the treatment of spinal muscular atrophy, and SRK-181, which is in clinical trials for the treatment of cancers resistant to checkpoint inhibitor therapies. Scholar Rock is also developing a pipeline of novel product candidates aimed at transforming the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. cholar Rock Holding Corp is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage